To include your compound in the COVID-19 Resource Center, submit it here.

Zogenix soars on Phase III data for Dravet syndrome candidate

Zogenix Inc. (NASDAQ:ZGNX) rocketed $22.17 (172%) to $35.05 on Friday, adding $550 million in market cap, after reporting that ZX008 as adjunctive therapy met the primary endpoint in the Phase III Study 1 to treat

Read the full 350 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE